Radnostix, Inc. Faces Challenges with Decline in Revenues and Operations in FY2026 Q1

Radnostix, Inc. FY2026 Q1 Results Overview

Radnostix, Inc. (formerly known as International Isotopes Inc.) recently announced its financial results for the first quarter of fiscal year 2026, revealing a stark 27% decrease in revenue compared to the same quarter last year. The total revenue fell to $2.38 million from $3.24 million in Q1 2025. This downturn primarily stemmed from voluntary product recalls, disruptions in isotope supply, and a planned operational shutdown affecting their Cobalt-60 hot cell.

Key Financial Highlights

1. Revenue Analysis: The decrease in total revenue is largely attributed to impacts from the aforementioned recalls, alongside significant downtime related to isotope shortages and the maintenance of the Cobalt-60 hot cell which occurred in late 2025. Gross profit also suffered, decreasing by 43% to $1.15 million from $2.03 million year-over-year.

2. Cash Flow Position: As of March 31, 2026, the company reported cash and cash equivalents of $1.35 million, down from $1.70 million at the end of 2025, indicating a cash outflow from operating activities amounting to approximately $72,442.

3. Operational Developments: Despite these setbacks, Radnostix completed the construction of its dedicated Calibration Reference Products manufacturing facility and received the initial amendment for its NRC license, positioning the company for significant growth and capacity expansion in the calendar year. Notably, the hot cell, which was down for over five months, was repaired and is now operational, adding approximately 15 to 20 years to its service life.

4. Strategic Asset Management: The company has also terminated its agreement to sell DUF6 assets, allowing full control of these strategic resources as global interest in nuclear energy continues to rise. This action opens doors for potential advancements in their uranium-related activities.

Executive Comments

Shahe Bagerdjian, the President and CEO of Radnostix, expressed that the company confronted multiple operational and supply-chain challenges during Q1. The unanticipated recalls impacted both the revenues and profit margins significantly. However, he remains optimistic that these issues should not extend beyond Q2 2026. The planned maintenance of the hot cell, while temporarily constricting, is a necessary investment for the company’s long-term reliability and quality assurance. Bagerdjian outlined ongoing corrective actions for FDA observations and efforts to restore I-131 capsule inventory while qualifying additional isotope suppliers.

Future Outlook

Looking ahead to the remainder of 2026, Radnostix aims to strategically explore enhancements related to its DUF6 assets, reflecting renewed interest in uranium fuel cycle services expected in the second quarter. The company plans to fully launch innovative products such as the EasyFill Automated Capsule System and enhance their product line as they continue building out the Calibration Reference Products facility. Furthermore, they anticipate submitting a GMP API drug master file for I-131 intended for theranostics applications by Q4 2026.

In summary, while the Q1 results show substantial challenges, Radnostix is undertaking significant efforts to stabilize operations and pursue growth opportunities, indicating a hopeful outlook for the coming quarters.